Publications

Adaptimmune and Immunocore Publications

Bossi G, Gerry AB, Paston SJ, Sutton DH, Hassan NJ & Jakobsen BK. (2013) Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells Oncoimmunology. 2013 Nov 1; 2(11):e26840.

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK. (2013) Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells
Sci Transl Med. 2013 Aug 7; 5(197):197ra103.

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH. (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Blood. 2013 Aug 8; 122(6):863-71. doi: 10.1182/blood-2013-03-490565.

Smethurst D. (2013) A pharmacologic perspective on newly emerging T-cell manipulation technologies Br J Clin Pharmacol. 2013 Aug; 76(2):173-87. doi: 10.1111/j.1365-2125.2012.04475.x.

Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK. (2012) Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012 May 6

Robbins PF1, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA. (2008) Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions J Immunol. 2008 May 1; 180(9):6116-31.

Varela-Rohena, A., Molloy, P. E., Dunn, S. M., Li, Y., Suhoski, M., Carroll, R. G., Milicic, A., Mahon, T., Sutton, D. H., Laugel, B. E., Moysey, R., Cameron, B. J., Vuidepot, A., Purbhoo, M. E., Cole, D. K., Phillips, R. E., June, C. H., Jakobsen, B. K., Sewell, A. K., and Riley, J. L. (2008) Control of HIV-1 immune escape by CD8 T-cells expressing enhanced T-cell receptor. Nat Med. 14 (12), 1390-5.

Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, Li Y, Molloy PE, Dunn SM, Jakobsen BK, Rosenberg SA, Morgan RA. (2007) High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines J Immunol. 2007 Nov 1; 179(9):5845-54.

Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, Price DA, Gao GF, Sewell AK, Jakobsen BK. (2007) Human TCR-binding affinity is governed by MHC class restriction. J Immunol. 2007 May 1;178(9):5727-34.

Yuan F, Georgiou T, Hillon T, Gostick E, Price DA, Sewell AK, Moysey R, Gavarret J, Vuidepot A, Sami M, Bell JI, Gao GF, Rizkallah PJ, Jakobsen BK. (2007) Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Sep 1;63(Pt 9):758-60.

Sami Malkit; Rizkallah Pierre J; Dunn Steve; Molloy Peter; Moysey Ruth; Vuidepot Annelise; Baston Emma; Todorov Penio; Li Yi; Gao Feng; Boulter Jonathan M; Jakobsen Bent K. (2007) Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Protein engineering, design & selection : PEDS 2007;20(8):397-403.

Purbhoo Marco A; Li Yi; Sutton Deborah H; Brewer Joanna E; Gostick Emma; Bossi Giovanna; Laugel Bruno; Moysey Ruth; Baston Emma; Liddy Nathaniel; Cameron Brian; Bennett Alan D; Ashfield Rebecca; Milicic Anita; Price David A; Classon Brendan J; Sewell Andrew K; Jakobsen Bent K. (2007) The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Molecular cancer therapeutics 2007; 6(7):2081-91.

Purbhoo Marco A; Sutton Deborah H; Brewer Joanna E; Mullings Rebecca E; Hill Maxine E; Mahon Tara M; Karbach Julia; Jäger Elke; Cameron Brian J; Lissin Nikolai; Vyas Paresh; Chen Ji-Li; Cerundolo Vincenzo; Jakobsen Bent K (2006) Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. Journal of immunology (Baltimore, Md. : 1950) 2006;176(12):7308-16.

Dunn Steven M; Rizkallah Pierre J; Baston Emma; Mahon Tara; Cameron Brian; Moysey Ruth; Gao Feng; Sami Malkit; Boulter Jonathan; Li Yi; Jakobsen Bent K. (2006)  Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein science: a publication of the Protein Society 2006; 15(4):710-21.

Li Yi; Moysey Ruth; Molloy Peter E; Vuidepot Anne-Lise; Mahon Tara; Baston Emma; Dunn Steven; Liddy Nathaniel; Jacob Jansen; Jakobsen Bent K; Boulter Jonathan M. (2005)  Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nature biotechnology 2005;23(3):349-54.

Boulter Jonathan M; Glick Meir; Todorov Penio T; Baston Emma; Sami Malkit; Rizkallah Pierre; Jakobsen Bent K. (2003) Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein engineering 2003; 16(9):707-11

Key publications on Adoptive Cellular Immunotherapy for Cancer and Viral Diseases

Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH. (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012 May 2; 4(132):132ra53

June C, Rosenberg SA, Sadelain M, Weber JS. (2012) T-cell therapy at the threshold. Nat Biotechnol. 2012 Jul 10; 30(7):611-4.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O’Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. (2011) Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9(1):214.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011 Aug 10; 3(95):95ra73.

Porter DL, Levine BL, Kalos M, Bagg A, June CH. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011 Aug 25; 365(8):725-33.

Porter DL, Kalos M, Zheng Z, Levine B, June C. (2011) Chimeric Antigen Receptor Therapy for B-cell Malignancies. J Cancer. 2011; 2:331-2.

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.(2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 1; 29(7):917-24.

June CH. (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007 Jun; 117(6):1466-76.

June CH. (2007) Principles of adoptive T cell cancer therapy.  J Clin Invest. 2007 May;117(5):1204-12.

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 1; 23(10):2346-57.